362PASSESSMENT OF TREATMENT RESPONSE WITH FULVESTRANT (F) 500 MG IN STANDARD CLINICAL PRACTICE THROUGH A RETROSPECTIVE STUDY: NCT01509625

Abstract Aim: After CONFIRM study results, fulvestrant 500 mg (F500) became one of the standard treatments for patients with oestrogen receptor (ER+) Metastatic Breast Cancer (MBC) who previously had progressed on hormonal treatment. The aim of this study is to describe the efficacy of F500 in terms...

Full description

Bibliographic Details

Published in:	Annals of oncology Vol. 25; no. suppl_4; p. iv120
Main Authors:	Blancas, I., Fontanillas, M., Conde Herrero, V., Lao, J., Martinez de Dueñas, E., Sotelo Lezama, M., JaÉn-Morago, A., Bayo, J.L., Carabantes, F., Illaramendi, J.J., Gordón, M., Ruiz-Borrego, M., Cruz, J., García-Palomo, A., Mendiola, C., Perez-Ruiz, E., Cañada, J.M. Baena, Martínez, N., Esquerdo, G., Bofill, J. Salvador
Format:	Journal Article
Language:	English
Published:	Oxford University Press 01-09-2014
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!